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Abstract 
Triple antiplatelet therapy (TAPT, or triple therapy), is an 
oral medication regimen designed to reduce the risk of ma-
jor cardiovascular events. It consists of aspirin, clopidogrel 
or an alternative, and an oral anticoagulant (OAC). It differs 
from dual antiplatelet therapy (DAPT) due to inclusion of an 
OAC. Multiple clinical studies have indicated that triple ther-
apy is more effective at clot prevention, when compared to 
aspirin monotherapy and DAPT, but is associated with a 
higher risk of major bleeding. Pharmacists have a key role in 
determining candidates for DAPT and T APT regimens. Other 
opportunities for pharmacists include patient monitoring, 
counseling and medication review throughout treatment 
with antithrombotic therapy. 
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Introduction 
Dual antiplatelet therapy (DAPT) consists of aspirin and 
clopidogrel (or an alternative). It is used to prevent throm-
bosis and inhibit platelet function for patients with coronary 
artery disease (CAD), atherosclerotic ischemic stroke, atrial 
fibrillation (AF) or acute coronary syndrome (ACS) with or 
without percutaneous coronary intervention (PCI). 1 Howev-
er, the introduction of an additional antiplatelet agent to the 
regimen leads to an increased risk of bleeding when com-
pared to aspirin monotherapy. In a study comparing the ef-
fectiveness of aspirin alone to a DAPT (aspirin-clopidogrel) 
regimen, there was a statistically significant decrease (95 
percent confidence interval (CI): 0.59-0.82, p < 0.05) in the 
incidence of stroke among those on DAPT.2 
Development of triple antiplatelet therapy (TAPT, or triple 
therapy) has led to controversy over the ideal number of 
antiplatelet/anticoagulant agents to provide the best effica-
cy for clot prevention while maintaining safety. The compo-
nents of TAPT are aspirin, clopidogrel or an alternative, and 
warfarin.3 Alternative antiplatelets to clopidogrel in either 
therapy include prasugrel and ticagrelor. Clopidogrel is a 
thienopyridine antiplatelet agent that acts by irreversibly 
blocking the P2Y 12 adenosine di phosphate (ADP) receptors 
on the platelet surface.4 This prevents activation of certain 
complexes that cause platelet aggregation. Since this action 
is irreversible, platelet aggregation is reduced. 
Prasugrel has a similar mechanism of action to clopidogrel.5 
A clinical trial assessed therapeutic outcomes using prasug-
rel in comparison to clopidogrel in patients with myocardial 
infarction (MI). The primary endpoints were death from 
cardiovascular (CV) causes, nonfatal MI and nonfatal stroke. 
The secondary outcomes were stent thrombosis and 
planned PCI for patients enrolled in the study with acute 
coronary syndrome. The results of this study showed that 
there was a reduced death rate from MI for subjects taking 
prasugrel compared to those taking clopidogrel. However, 
the prasugrel group experienced increased bleeding (1.4 
percent in the prasugrel group versus 0.9 percent in the 
clopidogrel group, p=0.01).5 Prasugrel is a more potent in-
hibitor of platelet aggregation than clopidogrel due to higher 
exposure of the metabolite to the receptor. It is well-
absorbed and metabolized by the body and inhibits platelet 
aggregation within 30 minutes of administration. In compar-
ison, clopidogrel has a median onset of inhibition of 1.5 
hours.6 It is suggested to weigh the benefits of prasugrel as 
an antiplatelet agent against its risks for bleeding as com-
pared to clopidogrel. 
Another antiplatelet agent used in place of clopidogrel is 
ticagrelor which acts via reversible inhibition of the P2Y 12 
ADP receptor.7 Ticagrelor has been shown to have greater 
inhibition of the receptor than clopidogrel. In a study com-
paring the efficacy and safety of ticagrelor and clopidogrel in 
patients hospitalized for ACS, ticagrelor decreased rates of 
death due to vascular MI and stroke more than clopidogrel, 
with a hazard ratio of 0.84 (p < 0.001, 95 percent CI [0.77-
0.92]).7 Clopidogrel and ticagrelor did not differ in risk of 
bleeding, while prasugrel showed more intracranial and gas-
trointestinal bleeding than ticagrelor.5 This indicates that 
ticagrelor may be more effective as an antiplatelet agent, 
without the adverse effect of increased bleeding, as com-
pared to clopidogrel and prasugrel. 
An oral anticoagulant (OAC) is added to prevent stroke and 
other CV events. Despite the added benefits, traditional 
OACs introduce risks to the regimen, including an increased 
risk for bleeding, which can lead to worse health outcomes 
and decreased compliance.3 However, an OAC exhibits great-
er anticoagulation than aspirin and clopidogrel combined.a 
Novel oral anticoagulants (NOACs) may serve as alternatives 
to warfarin in the TAPT regimen.9 Several NOACs have been 
investigated in TAPT, including dabigatran, apixaban and 
rivaroxaban. Dabigatran is a factor Ila (thrombin) inhibitor, 
and apixaban and rivaroxaban are factor Xa inhibitors. Using 
NOACs over warfarin may be beneficial because NOACs are 
not vitamin K antagonists and have fewer side effects. There 
is also a lower risk of bleeding associated with some NOACs 
when compared with warfarin. In a study comparing warfa-
rin to dabigatran, rate of major bleeding was 3.57 percent 
per year in the warfarin group and 2.78 percent per year in 
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the dabigatran group (p=0.003).9 The more traditional vita-
min K antagonists do have a reversal option as vitamin K can 
be administered in the event of a bleed.10 While there is a 
reversal agent for dabigatran (idarucizumab), there is cur-
rently no reversal agent for rivaroxaban or apixaban. Anoth-
er risk associated with NOACs is liver injury, with reports 
that 1.8 to 3.9 percent of patients taking these medications 
experience unpredictable and severe liver injury or liver fail-
ure.11 
Therapy Selection 
Appropriate candidates for TAPT are PC! patients with stents 
implanted either electively or to treat ACS.3 A patient with 
stent implantation requires DAPT because monotherapy 
with aspirin is insufficient to prevent thrombosis. Triple an-
tiplatelet therapy may be suitable for these patients if they 
have a low risk of bleeding. Other candidates for TAPT in-
clude those with conditions that require stroke prevention as 
well as antiplatelet therapy, such as AF patients with ACS or 
mechanical valve patients with severe CAo.12.13 
Percutaneous coronary intervention with stent implantation 
(PCI-s) has become a routine procedure for many individuals 
with myocardial ischemia.14 In patients with AF who have 
undergone PCl-s, the decision to recommend TAPT is based 
on prevention of cardioembolic events associated with AF 
and stent thrombosis after PCI-s in addition to an assessment 
of bleeding risk. Combined aspirin-clopidogrel therapy is less 
effective in preventing stroke than OAC alone, but OAC alone 
is insufficient to prevent stent thrombosis.a Thus, TAPT is 
often recommended. In 2010, the European Society of Cardi-
ology (ESC) published a consensus document with the rec-
ommendation that all patients with AF who undergo PCI-s 
should receive TAPT for at least one month and up to 12 
months, depending on the type of stent used, the clinical indi-
cation (elective stent implantation versus ACS) and the pa-
tient's risk of hemorrhage.14 After bare metal stent (BMS) 
implantation, triple therapy should be utilized for two to four 
weeks followed by OAC monotherapy.a Drug-eluting stents 
(DES), on the other hand, require three to six months of tri-
ple therapy followed by OAC monotherapy. Second-
generation and third-generation DES may be preferred as 
they might be associated with shorter re-endothelialization 
times and shorter duration of triple therapy. However, the 
use of BMS is the ultimate preference in this population as 
the recommended duration of triple antithrombotic therapy 
is considerably shorter.14 
Individually, antiplatelet and anticoagulant agents increase a 
patient's risk of bleeding, and, when used in combination, 
they further worsen this risk. A meta-analysis consisting of 
nine clinical trials that included 1,996 participants found that 
T APT is associated with a twofold increase in major bleeding 
complications after PCI-s compared to DAPT in patients with 
an indication for long-term OAC.14 Major bleeding was de-
fined as an absolute decrease in hematocrit of more than 15 
percent, the need for transfusion of two or more units of 
blood, the need for corrective surgery, the occurrence of an 
intracranial or retroperitoneal hemorrhage or any combina-
tion of the aforementioned events.a Almost all reported ma-
jor bleeding events occurred in the first six months of follow 
up and were often associated with supratherapeutic interna-
tional normalized ratio (INR) levels. Additionally, most 
bleeding events occurred in the gastrointestinal (GI) system 
of patients with baseline anemia. Another study that exam-
ined 4,959 patients over the age of 65 with acute MI and AF 
who underwent coronary stenting found that incidence of 
bleeding requiring hospitalization within two years post-
discharge as well as incidence of intracranial hemorrhage, 
were significantly higher for patients discharged on T APT 
compared to DAPT.1s 
Specific mechanisms contributing to increased bleeding asso-
ciated with triple therapy have not yet been studied but are 
likely affected by various clinical and therapeutic factors 
such as advanced age, female gender, peri-interventional 
administration of glycoprotein lib/Illa inhibitors, smoking 
and high prevalence of comorbidities including renal dys-
function and previous major bleeding.a In the event that a 
major bleeding event should occur while a patient is on 
T APT, treatment should be aggressive. If minor bleeding 
events occur (defined as observed blood loss and 9 to 15 
percent decrease in hematocrit or decrease in hemoglobin 
level<':40 g/L if no bleeding is identified), antithrombotic 
therapy should not be discontinued because of the patient's 
increased risk of developing stent thrombosis or vascular 
throm boem bol ism. 
For patients in whom a NOAC is used in place of warfarin in 
T APT therapy, the lowest dose effective for stroke preven-
tion in AF should be considered.16 A meta-analysis involving 
30,866 patients with recent ACS concluded that the inclusion 
of a NOAC in a triple therapy regimen increased the bleeding 
risk by 79 to 134 percent while minimally decreasing recur-
rent ischemic events in patients without AF. Several other 
studies were conducted that evaluated triple therapy with 
rivaroxaban, apixaban or dabigatran combined with aspirin 
and clopidogrel in patients with ACS. Rivaroxaban was tested 
using subtherapeutic doses (2.5 mg twice daily or 5 mg daily) 
for complete anticoagulation because higher doses were 
found to produce a dose-dependent increase of bleeding 
risk.17,1a For this reason, use of rivaroxaban may not be pre-
ferred in triple therapy.16 Unlike rivaroxaban, apixaban in 
triple therapy was studied in doses recommended for com-
plete anticoagulation.19 The study was stopped prematurely 
because there was a significant 2.5-fold increase in risk of 
bleeding among the apixaban group compared to the placebo 
group with no indication of benefit in preventing MI, stroke 
or CV death.13 Thus, triple therapy with apixaban may not be 
preferred. Dabigatran in triple therapy was also found to be 
associated with dose-dependent increase of bleeding risk in 
patients with ACs.20 A substudy analysis of the RE-LY 
(Randomized Evaluation of Long-Term Anticoagulation 
Therapy) study was conducted to further assess the bleeding 
risk of dabigatran in T APT by comparing dabigatran 110 mg, 
dabigatran 150 mg, and warfarin.21 This study determined 
that dabigatran 110 mg twice daily is noninferior to warfarin, 
with fewer bleeding incidents regardless of concomitant an-
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tiplatelet use in patients with AF. While the relative risk of 
bleeding was found to be similar with dabigatran 110 mg, 
dabigatran 150 mg, and warfarin, the absolute risk was low-
est with dabigatran 110 mg. Overall, bleeding risk must be 
assessed and monitored with all NOACs. 
Despite the risks, TAPT is a viable option to consider for 
many patients, especially those with a higher risk of throm-
botic events and a lower risk of bleeding events.a Conducting 
a risk assessment of bleeding and ischemic complications is 
highly advised for all patients who are candidates for T APT. 
Triple therapy should not be continued long-term after PCl-s 
in patients with a high bleeding risk profile as even mild to 
moderate bleeding events are associated with poorer long-
term prognosis. However, lowering the dosage of aspirin to 
less than or equal to 100 mg/day in the triple therapy regi-
men may reduce the occurrence of major or minor bleeding 
events.22 In patients with low risk of bleeding complications, 
TAPT should be highly considered as the elective antithrom-
botic drug treatment approach.a 
In spite of being associated with increased risk of bleeding, 
T APT has been found to be more efficacious in lowering 
mortality in patients with AF and PCI compared to DAPT in 
addition to reducing major adverse CV events, including 
death or hospital readmission for Ml, ischemic stroke or 
hemorrhagic stroke.15 The meta-analysis discussed previ-
ously consisting of nine clinical trials demonstrated a 40 per-
cent relative reduction in major adverse cardiac events and a 
41 percent relative reduction in all-cause mortality.14 Reduc-
tion in major adverse CV events is due to the lower occur-
rence of thrombotic and embolic events in the TAPT group.a 
Furthermore, reduction in all-cause mortality occurs as a 
direct result of significant reduction in major adverse CV 
events in the triple therapy group. One retrospective study 
conducted in Spain by Ruiz-Nodar et al. supports this conclu-
sion.23 The study included a cohort of 426 patients with AF 
who underwent PCl-s, 50 percent of whom were discharged 
on T APT and 40.8 percent of whom were discharged on 
DAPT. Upon completion of a multivariate analysis, it was 
found that patients who received TAPT had a lower all-cause 
mortality rate (17.8 percent versus 27.8 percent, p=0.002) 
and lower major adverse cardiac event rate (26.5 percent 
versus 38.7 percent, p=0.001) compared to patients receiv-
ing DAPT. 
Therapy Considerations and the Role of the Pharmacist 
Due to the high risk of bleeding, the 2014 American College 
of Cardiology and the American Heart Association Task 
Force on Practice Guidelines recommends refraining from 
the long-term use of T APT due to exponential increase in 
bleeding risk.24 Additionally, DAPT is recommended to be 
utilized after PCI. However, the 2016 ESC Guidelines recom-
mend the use of an OAC after stenting in patients with a his-
tory of deep vein thrombosis and pulmonary embolism and 
in AF patients with a stroke risk. This expert-based consen-
sus suggests that T APT should be used in these patients but 
only for a short duration.16 Based on the ESC guidelines, clin-
ical judgment influenced by thrombotic risk should be used 
to determine whether or not therapy should be supplement-
ed by an OAC. 
When the T APT regimen is selected, regular monitoring for 
bleeding risk is advised upon discharge. Pharmacists play a 
critical role in the monitoring process, especially when the 
OAC of choice is warfarin. Upon discharge, patients on warfa-
rin should be referred for anticoagulation monitoring so that 
the INR can be assessed regularly. INR is a key indicator of 
bleeding risk in those patients who are receiving warfarin.e 
Because of this increased bleeding risk with T APT, the target 
range is lower and narrower than a typical warfarin treat-
ment plan. The recommended goal INR for these patients is 
2.0 to 2.5 as compared to the typical therapeutic INR range 
of 2.0 to 3.Q.16,24-25 This narrower INR range for TAPT 
patients is recommended but with low evidence since this 
target INR range has not been evaluated in many patient 
populations and is based solely on expert opinion.24 Pharma-
cists may also utilize the HAS-BLED method for assessment 
of other disease states and lifestyle factors to monitor risk of 
bleeding in select patients. The HAS-BLED method is based 
on seven factors: hypertension, abnormal renal/liver func-
tion, stroke, bleeding history or predisposition, labile INR, 
elderly and drugs/alcohol concomitantly which all contrib-
ute to the risk of bleeding for an AF patient.14 
Discussion with TAPT patients is necessary so that health 
care providers can identify potential drug interactions, 
adverse effects, effective ways to educate and other drug 
therapies a patient is using. This necessary information is 
obtained best by addressing patient concerns, asking open-
ended questions, listening to patient responses in their en-
tirety and assessing patient adherence based on previous 
medical history.14 In particular, warfarin is known to have 
many drug interactions that can be identified by talking to 
patients. All patients should be educated regarding warfa-
rin's potential to react with specific medications, which 
could result in altered effects of warfarin. A common list of 
medications that interact with warfarin should be provided 
to patients. Additionally, the patient should receive educa-
tion on how to identify bleeding risks with the biggest identi-
fier as bruising.14 In order to prevent GI bleeds, the use of 
proton pump inhibitors (PPis), Hz antagonists and antacids 
is common in T APT patients and is recommended in patients 
with a history of GI bleeding.16,24,26 However, close monitor-
ing is advised to ensure efficacy because clopidogrel and 
PPis are metabolized by CYP2Cl 9 which can decrease the 
effects of clopidogrel due to competitive binding. While be-
ing treated with T APT that includes clopidogrel, patients 
should only be on PP Is if there is a specific indication to treat 
a disease state such as chronic heartburn or if it will benefit 
the patient by protection from GI bleeding.26These discus-
sions can happen in anticoagulation clinics, in community 
pharmacies and prior to discharge at the hospital. 
Pharmacists must work with other health care providers to 
promote the continuum of care for each patient, especially 
while in the hospital. Pharmacists have a role in the medica-
tion reconciliation process before and after PC! to ensure 
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that T APT candidates will receive the best and safest out-
comes while on the therapy. Even though pharmacists in an-
ticoagulation clinics will be assessing the INR of patients on 
warfarin after discharge, assessment of CHADS2 scores for 
stroke risk in AF patients, INR monitoring and HAS-BLED are 
critical while in the hospital.14 For those patients on NOACs, 
HAS-BLED remains an effective monitoring tool. All of this 
information should be communicated with all health care 
providers involved with the care of each patient. 
Conclusion 
Overall, when choosing a treatment regimen for a patient in 
need of anticoagulation therapy, it is important to evaluate 
the benefits of using T APT as well as its risks in comparison 
to DAPT. While T APT has shown to be more effective at pre-
venting thrombosis, the increased risk of bleeding may cause 
harm in patients who are already at high risk to develop 
bleeds. However, T APT is recommended for specific patient 
populations such as patients with ACS undergoing PCI-s or 
patients with a mechanical heart valve with severe CAD as 
these patients require more aggressive anticoagulation 
therapy. This recommendation is based on expert opinion. In 
order to obtain evidence-based recommendations, further 
research needs to be done comparing long-term outcomes of 
TAPT and DAPT in various patient populations. The safety of 
patients on TAPT is dependent on careful monitoring of 
treatment by health care professionals and thorough patient 
education about medication adherence, proper medication 
usage and the warning signs of bleeding. 
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